Infectious Diseases

Top Medical News
Fewer hospitalizations with omicron vs delta suggest reduced severity of omicron variant
Roshini Claire Anthony, Yesterday

Infection with the omicron variant of SARS-CoV-2 was less likely to result in hospitalization than infection with the delta variant, according to an observational study from Denmark presented at ECCMID 2022 and published in The Lancet.

Omicron vaccines to start clinical trials in HK
Tristan Manalac, Yesterday
Getting a different type of mRNA vaccine for the booster shot leads to a stronger neutralizing immune response against the COVID-19 Omicron variant, according to a recent Singapore study.
Older persons should obtain annual influenza vaccine.
Rachel Soon, Yesterday
Influenza prevention measures for older persons must be intensified as the COVID-19 pandemic transitions into an endemic phase, urge health experts.
Energy deficit improves within the first week of severe septic shock
3 days ago
In patients suffering from severe septic shock, energy deficit improves during the first week of intensive care unit stay, accompanied by relatively stable resting energy expenditure and respiratory quotient, a recent study has found.
Male sex, obesity among risk factors for severe COVID-19 in children
Roshini Claire Anthony, 4 days ago

A large study by the US National COVID Cohort Collaborative (N3C) has identified factors associated with the risk of severe disease among children with SARS-CoV-2 infection as well as factors tied to an increased risk of multisystem inflammatory syndrome in children (MIS-C) as compared to acute COVID-19.

Investigational drug gains upper hand over placebo in reducing CDI recurrence rates
Audrey Abella, 4 days ago
SER-109, an investigational oral microbiome therapeutic, achieves superiority over placebo in reducing recurrent Clostridioides difficile infection (CDI) rates, according to updated findings from the phase III ECOSPOR-III trial.
Special Reports
Kids hard-hit by Delta; which ART performs best?
Elvira Manzano, 24 Oct 2021
That COVID-19 mostly spared children might be changing. The Delta variant has taken a severe, unthinkable toll on kids – at least in Arkansas, US, reports an expert at IDWeek 2021.
Rapid antigen test: Don’t let perfect be the enemy of good
Pearl Toh, 23 Oct 2021
While rapid antigen test is less sensitive than conventional nucleic acid amplification test (NAAT) such as RT-PCR* in detecting SARS-CoV-2 virus, “a test does not have to be perfect to be clinically useful,” said Professor Angela Caliendo during a session in IDWeek 2021 — echoing the maxim that perfect should not be the enemy of good in the pandemic era.
ID NOW rapid molecular assay an effective COVID-19 test for kids
Roshini Claire Anthony, 20 Oct 2021

A large retrospective study from the US, presented at IDWeek 2021, has shown that the Abbott ID NOW rapid molecular COVID-19 assay is highly sensitive and specific at detecting SARS-CoV-2 infection in a paediatric population.

Product Highlight - Cresemba
29 Sep 2021
Isavuconazole 100 mg hard cap and 200 mg infusion conc
Antigen rapid tests: The new COVID-19 strategy moving forward?
Roshini Claire Anthony, 31 Jul 2021

Same-day pre-event screening for SARS-CoV-2 using antigen-detecting rapid diagnostic tests (Ag-RDT) may enable the resumption of large-scale indoor events which were halted or had their attendance capacity reduced during the COVID-19 pandemic, according to a study from Spain presented at ECCMID 2021.

Combined Ag/Ab rapid testing boosts case-finding in COVID-19
Elvira Manzano, 29 Jul 2021
A rapid and affordable test for diagnosing COVID-19 outside the walls of the healthcare units could improve case-finding, contact tracing, and infection control, says an expert during a pre-ECCMID 2021 session.
Conference Reports
Fewer hospitalizations with omicron vs delta suggest reduced severity of omicron variant
Roshini Claire Anthony, 23 May 2022

Infection with the omicron variant of SARS-CoV-2 was less likely to result in hospitalization than infection with the delta variant, according to an observational study from Denmark presented at ECCMID 2022 and published in The Lancet.

Investigational drug gains upper hand over placebo in reducing CDI recurrence rates
Audrey Abella, 20 May 2022
SER-109, an investigational oral microbiome therapeutic, achieves superiority over placebo in reducing recurrent Clostridioides difficile infection (CDI) rates, according to updated findings from the phase III ECOSPOR-III trial.
AZD7442 effectively TACKLEs COVID-19
Audrey Abella, 12 May 2022
The phase III TACKLE trial highlights a new player in the COVID-19 treatment field – AZD7442 (tixagevimab/cilgavimab) – which demonstrated favourable efficacy and safety for nonhospitalized individuals with mild to moderate symptoms of the disease.
Remdesivir benefit greatest when given early in COVID-19
Pearl Toh, 11 May 2022
Treatment with remdesivir is associated with reduced risk of hospitalization and death in non-hospitalized and hospitalized COVID-19 patients, respectively, especially when given early during the disease course, according to studies presented at ECCMID 2022.
Sotrovimab reduces hospitalization, death in patients with COVID-19 regardless of serostatus
Elaine Soliven, 23 Mar 2022
Treatment with sotrovimab reduces the risk of all-cause hospitalization or death in patients with COVID-19 who are at high risk of progression to severe disease, regardless of anti-SARS-CoV-2 serostatus, according to a study presented at CROI 2022.
Booster COVID-19 vacc cuts breakthrough infection risk
Roshini Claire Anthony, 17 Mar 2022

Receipt of a booster dose of the COVID-19 vaccine reduces the risk of breakthrough COVID-19 infections* compared to full vaccination only, particularly among individuals without immunosuppressed/compromised conditions (ISC), according to a US study presented at CROI 2022.

Post-COVID sequelae conditions identified, could help establish definition
Roshini Claire Anthony, 08 Mar 2022

Patients diagnosed with COVID-19 could have an increased risk of certain conditions up to 120 days post-diagnosis, a finding which could help establish the definition of Post-Acute Sequelae of SARS-CoV-2 Infection (PASC), according to a study presented at CROI 2022.